Key Highlights
- Psyence BioMed will invest up to 5 million dollars in PsyLabs, with 2.4 million already committed.
- A share exchange valued at approximately 9 million dollars per side will increase mutual ownership stakes.
- The Company is evaluating a potential ibogaine trial in Texas for opioid use disorder.
- Post-transaction, PsyLabs will hold ~49.89% of PBM shares; PBM will hold ~41.13% of PsyLabs shares.
A strategic alignment between clinical and Manufacturing partners
Psyence Biomedical Ltd. (NASDAQ:PBM), a biopharmaceutical company developing nature-derived neuroplastogen therapeutics, has announced a cash Investment of up to 5 million dollars in Psyence Labs Ltd., alongside a value-matched share exchange between the two companies. The transactions, announced on September 23, 2026, are intended to support scientific development and pharmaceutical-grade manufacturing capabilities relevant to the company's planned US ibogaine program.
The announcement follows the establishment of Texas Ibogaine Research Corporation, a dedicated US Subsidiary created to coordinate the company's regulatory, clinical and development activities involving pharmaceutical-grade ibogaine. The Company is currently evaluating the feasibility and design of a potential clinical trial in Texas targeting opioid use disorder, though any such program remains subject to protocol development, regulatory review, institutional approvals and other customary requirements.
Psyence BioMed has irrevocably committed 2.4 million dollars of the total 5 million dollar investment, structured as shares in PsyLabs' current financing round, with the remaining balance structured as a milestone-based backstop commitment that will lapse if not called by the end of 2026.
A related-party transaction reshaping cross-ownership structure
The transaction's structure reveals a deepening, already-existing relationship between the two companies rather than an entirely new partnership. Prior to these transactions, PsyLabs held approximately 30.22% of Psyence BioMed's issued shares, while Psyence BioMed held approximately 29.17% of PsyLabs' shares, meaning both companies were already significant shareholders in one another before this latest round of investment.
Following completion of the share exchange and the committed portion of the cash investment, these cross-holdings will increase substantially, with PsyLabs set to hold approximately 49.89% of Psyence BioMed's shares and Psyence BioMed holding approximately 41.13% of PsyLabs' shares. This meaningfully deepens the ownership interlock between the two entities, a structure management has framed as aligning clinical and regulatory development activities more closely with pharmaceutical-grade manufacturing and Supply capabilities.
Because both the cash investment and share exchange are classified as related-party transactions, the terms agreed may differ from what unrelated parties might negotiate independently, a Factor the company has explicitly flagged as a risk consideration. The share exchange values each side at approximately 9 million dollars, with Psyence BioMed issuing shares at a deemed price of 6 dollars per share and PsyLabs shares valued based on an independent third-party valuation implying a 60 million dollar Equity value for PsyLabs.
Balancing strategic supply chain alignment against execution and regulatory uncertainty
The investment may provide Psyence BioMed with more direct influence over pharmaceutical-grade ibogaine supply, a capability the company has described as fundamental to its planned US program. Establishing dedicated infrastructure through Texas Ibogaine Research Corporation, combined with closer alignment to PsyLabs' manufacturing platform, could streamline the regulatory and supply chain coordination needed to support a future clinical trial, should one proceed.
However, meaningful uncertainties remain at multiple levels. No clinical trial has been commenced, and no regulatory application has been filed or accepted for the Texas program at this stage. Ibogaine also remains classified as a controlled substance in the United States, and the company has explicitly noted that neither the FDA nor other regulatory authorities have approved ibogaine or its other neuroplastogen compounds for therapeutic use, with safety and efficacy not yet established through authorized clinical research.
Additional risk factors include the dilutive impact of the share exchange on existing shareholders, the concentrated ownership structure resulting from increased cross-holdings, and the possibility that the transactions may not close on the terms or timetable currently expected, given they remain subject to corporate approvals, regulatory clearance and Nasdaq notification requirements, with a November 30, 2026 deadline for the share exchange specifically.
Conclusion
This investment and share exchange reflect Psyence BioMed's strategy of deepening its ownership alignment with PsyLabs to secure pharmaceutical-grade ibogaine manufacturing capabilities ahead of a potential US clinical program. While the structure may streamline supply chain coordination for a future Texas-based trial targeting opioid use disorder, the transactions remain related-party in nature and contingent on multiple regulatory and corporate approvals. The path toward an actual clinical trial remains at an early evaluation stage, with meaningful regulatory and execution risk still ahead.



_11_19_2026_18_10_09_455845.jpg)

_11_19_2026_18_15_38_890267.jpg)
Please wait processing your request...